Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hongwei Xu

Showing results (441-450 of 455) with videos related to

Pageof 46
Sort By:
Blood Cancer Journal|November 6, 2024
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stagesYan Cheng, Fumou Sun, Daisy V Alapat, et al.
The Journal of Clinical Investigation|July 26, 2022
CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiationDongzheng Gai, Jin-Ran Chen, James P Stewart, et al.
Chinese Medical Journal|April 13, 2023
Individualized red-cell transfusion strategy for non-cardiac surgery in adults: a randomized controlled trialRen Liao, Jin Liu, Wei Zhang, et al.
Journal of Hematology & Oncology|June 29, 2023
A gene signature can predict risk of MGUS progressing to multiple myelomaFumou Sun, Yan Cheng, Jun Ying, et al.
Science Immunology|May 3, 2024
Oxidative phosphorylation regulates B cell effector cytokines and promotes inflammation in multiple sclerosisRui Li, Yanting Lei, Ayman Rezk, et al.
Nature Communications|January 19, 2024
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growthFumou Sun, Yan Cheng, Visanu Wanchai, et al.
Cancer Research|September 12, 2025
Inhibition of GSK3 and TSC2 Mediates the Oncogenic Activity of AKT in Hepatocellular CarcinomaGuofei Cui, Yi Zhou, Weiting Liao, et al.
Cancer Research|November 17, 2019
A Small-Molecule Inhibitor Targeting TRIP13 Suppresses Multiple Myeloma ProgressionYingcong Wang, Jing Huang, Bo Li, et al.
Gastroenterology|April 30, 2022
β-Catenin Sustains and Is Required for YES-associated Protein Oncogenic Activity in CholangiocarcinomaYi Zhang, Hongwei Xu, Guofei Cui, et al.
Blood|November 16, 2006
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1John D Shaughnessy, Fenghuang Zhan, Bart E Burington, et al.
Pageof 46

Showing results (441-450 of 455) with videos related to

Sort By:
Pageof 46
Blood Cancer Journal|November 6, 2024
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stagesYan Cheng, Fumou Sun, Daisy V Alapat, et al.
The Journal of Clinical Investigation|July 26, 2022
CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiationDongzheng Gai, Jin-Ran Chen, James P Stewart, et al.
Chinese Medical Journal|April 13, 2023
Individualized red-cell transfusion strategy for non-cardiac surgery in adults: a randomized controlled trialRen Liao, Jin Liu, Wei Zhang, et al.
Journal of Hematology & Oncology|June 29, 2023
A gene signature can predict risk of MGUS progressing to multiple myelomaFumou Sun, Yan Cheng, Jun Ying, et al.
Science Immunology|May 3, 2024
Oxidative phosphorylation regulates B cell effector cytokines and promotes inflammation in multiple sclerosisRui Li, Yanting Lei, Ayman Rezk, et al.
Nature Communications|January 19, 2024
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growthFumou Sun, Yan Cheng, Visanu Wanchai, et al.
Cancer Research|September 12, 2025
Inhibition of GSK3 and TSC2 Mediates the Oncogenic Activity of AKT in Hepatocellular CarcinomaGuofei Cui, Yi Zhou, Weiting Liao, et al.
Cancer Research|November 17, 2019
A Small-Molecule Inhibitor Targeting TRIP13 Suppresses Multiple Myeloma ProgressionYingcong Wang, Jing Huang, Bo Li, et al.
Gastroenterology|April 30, 2022
β-Catenin Sustains and Is Required for YES-associated Protein Oncogenic Activity in CholangiocarcinomaYi Zhang, Hongwei Xu, Guofei Cui, et al.
Blood|November 16, 2006
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1John D Shaughnessy, Fenghuang Zhan, Bart E Burington, et al.
Pageof 46